STALICLA news

STALICLA announces first patients enrolled in EU/US multicenter data collection biosampling study

The launch of the STA-B-001 study will accelerate the recruitment of participants for STP1 and STP2 Phase 2 trials. The multicenter trial will also enable deep clinical and biological data collection to strengthen STALICLA’s platform.

Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDD

Oct. 26, 2022

Innovative SME recognition

STALICLA DDS has been awarded innovative SME status by the Spanish Ministry of Economy and Competitiveness

The General Secretary of Innovation from the Spanish Ministry of Economy and Competitiveness has recently granted STALICLA DDS the status of innovative SME ("PYME innovadora"). The seal is an acknowledgement of STALICLA`s R&D activities and has been granted for a period of 3 years (valid till 16/09/2025)

Oct. 18, 2022

Women in Data Science congress sponsorship

STALICLA sponsoring the `Women in Data Science` event organized by Barcelona Biomedicine

The Women in Data Science (WiDS) initiative promotes training and engagement of data scientists worldwide, regardless of gender, with an emphasis on supporting women working in the field. Women in Data Science congress is a unique event that brings together data scientists in the field of biomedicine in Barcelona. The event, which took place on September 28, 2022 at the Auditorium of th

Oct. 18, 2022

STALICLA strengthens pipeline to advance precision medicine for Autism Spectrum Disorders

STALICLA SA, a precision neuroscience clinical stage biotech advancing the first precision medicine platform for patients with Neurodevelopmental Disorders, has in-licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. The first indication targets a biologically characterised subgroup of patients with Autism Spectrum Disorder (ASD)

STALICLA`s unique approach addresses a major weakness in the drug development process for Neurodevelopmental D

Oct. 11, 2022

STALICLA to in-license SFX-01 from Evgen for neurodevelopmental disorder indications

STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).

STALICLA`s unique approach addresses a major weak

Oct. 10, 2022

STALICLA will be leading computational drug repositioning in EU-funded project REPO4EU

STALICLA will play a key role in the consortium to build the Euro-Global Platform for Mechanism-based Drug Repurposing (REPO4EU), with an allocated budget of 1.7M to STALICLA Discovery and Data Science (DDS) unit.

REPO4EU consortium aims to address the urgent need to develop new cost-effective therapies as well as to improve existing treatments through international cooperation, pooling research and innovation expertise, and know-how worldwide. Among 13 proposals, REPO4EU i

Jul. 20, 2022

STALICLA completes successful phase 1b trials for the first precision medicine in autism spectrum disorder

Clinical data clear major test for the first precision neurodevelopmental disorders discovery platform, with a first application in Autism Spectrum Disorder (ASD)

STALICLA, a Swiss clinical stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), announced today the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for a first a

Mar. 24, 2022